1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Poland >
  5. Qiagen N.V Acquires BLIRT

M&A Deal Summary

Qiagen N.V Acquires BLIRT

On May 11, 2022, Qiagen N.V acquired life science company BLIRT

Acquisition Highlights
  • This is Qiagen N.V’s 7th transaction in the Life Science sector.
  • This is Qiagen N.V’s 1st transaction in Poland.

M&A Deal Summary
Date 2022-05-11
Target BLIRT
Sector Life Science
Buyer(s) Qiagen N.V
Deal Type Add-on Acquisition

Target

BLIRT

Gdańsk, Poland
BLIRT develops, manufactures and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. Its offering includes proteins and enzymes that are critical to the life sciences industry and diagnostic kit manufacturers, especially for non-COVID-19 applications. BLIRT was founded in 1994 and is based in Gdansk, Poland.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Qiagen N.V

Venlo, Netherlands
Category Company
Founded 1984
Sector Life Science
Employees5,200
Revenue 1.5B USD (2019)
DESCRIPTION

QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Qiagen was founded in 1986 and is based in Venlo, the Netherlands.

DEAL STATS #
Overall 15 of 17
Sector: Life Science M&A 7 of 8
Type: Add-on Acquisition M&A Deals 14 of 16
Country: Poland M&A 1 of 1
Year: 2022 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-17 NeuMoDx Molecular

Ann Arbor, Michigan, United States

NeuMoDx Molecular, Inc. designs and develops revolutionary molecular diagnostic solutions for hospital and clinical reference laboratories. NeuMoDx Molecular was founded in 2012 and is based in Ann Arbor, Michigan.

Buy $248M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-09 Verogen

San Diego, California, United States

Verogen is a developer, manufacturer, and sells forensic genomics products and services, including for next-generation sequencing. Verogen was formed in 2017 and is based in San Diego, California.

Buy $150M
Mergr

Solution for

Product

Company

Legal